Uptake Transporters | Onset of Expression/Activity | Adult Levels Reached | Age-Related Changes (% of Adult) in Expression/Activity after Birth | Comments | References |
---|---|---|---|---|---|
ASBT | |||||
mRNA expression | Fetal development (0.17%) | NR | Increased rapidly | Adult age: 60 days. Strain: C57BL/6J (M). Methods: RNA-seq | Cui et al. (2012a) |
ENT1 | |||||
mRNA expression | Fetal development (>100%) | 15 days | Inconsistent pattern | Statistical differences in expression between CV and GF strains (Selwyn et al., 2015). Adult age: 60 days (Cui et al., 2012a) and 90d43. Strain: C57BL/6J (Cui et al., 2012a) and CV + GF (Selwyn et al., 2015) (M). Methods: RNA-seq (Cui et al., 2012a) and RT-PCR43 | Cui et al. (2012a); Selwyn et al. (2015) |
ENT3 | |||||
mRNA expression | Fetal development (253%) | 25 days | Inconsistent pattern | Adult age: 60 days. Strain: C57BL/6J (M). Methods: RNA-seq | Cui et al. (2012a) |
NTCP | |||||
mRNA expression | Fetal development (17%) | F: 30 days. M: 0 days | Inconsistent pattern | Adult age: 56 (Cheng et al., 2007), 60 days (Cui et al., 2012a), 90d43. Strain: C57BL/6J (Cheng et al., 2007; Cui et al., 2012a) (mixed) and CV + GF (Selwyn et al., 2015) (M). Methods: bDNA (Cheng et al., 2007), RNA-seq, (Cui et al., 2012a) and RT-PCR43. | Cheng et al. (2007); Cui et al. (2012a); Selwyn et al. (2015) |
Protein expression | NR (15 days: CV 95%; GF 75%) | NR | Inconsistent pattern | Statistical differences in expression between CV and GF strains (Selwyn et al., 2015). Adult age: 90 days. Strain: CV + GF (M). Methods: Western blotting | Selwyn et al., 2015) |
OAT2 | |||||
mRNA expression | 1 days (0.6%) | 60 days | Increased progressively | Adult age: 60 days. Strain: C57BL/6J (M). Methods: RNA-seq | Cui et al. (2012a) |
OAT3 | |||||
mRNA expression | Fetal development (48372%) | 25–30 days | Decreased progressively | Adult age: 60 days. Strain: C57BL/6J (M). Methods: RNA-seq | Cui et al. (2012a) |
OATP1A1 | |||||
mRNA expression | Fetal development (0.01%–0.77%) | 30–40 days | Increased slowly | Adult age: 45 days (Cheng et al., 2005), 60 days (Cui et al., 2012a), 90 days (Selwyn et al., 2015). Strain: C57BL/6J (Cheng et al., 2005; Cui et al., 2012a) (mixed) and CV + GF (Selwyn et al., 2015) (mixed). Methods: RNA-seq (Cui et al., 2012a) and RT-PCR (Cheng et al., 2005; Cui et al., 2012a) (Selwyn et al., 2015) | Cheng et al. (2005); Cui et al. (2012a); Selwyn et al. (2015) |
OATP1A4 | |||||
mRNA expression | M: fetal development (35%). F: fetal development (4%) | M: 5–10 days. F: 23 days | Increased slowly | Adult age: 45 days (Cheng et al., 2005) and 60 days (Cui et al., 2012a; Li et al., 2016). Strain: C57BL/6 (mixed). Methods: bDNA (Cheng et al., 2005), RNA-seq (Cui et al., 2012a), and RT-PCR (Cui et al., 2012a; Li et al., 2016). | Cheng et al. (2005); Cui et al. (2012a); Li et al. (2016) |
Protein expression | NR | 5 days | NR | Adult age: 60 days. Strain: C57BL/6 (M). Methods: Western blotting | Li et al. (2016) |
OATP1A6 | |||||
mRNA expression | M: fetal development (57%). F: fetal development (32%) | M: 5 days. F: 10–15 days | Increased slowly | Adult age: 45 days. Strain: C57BL/6 (mixed). Methods: bDNA | Cheng et al. (2005) |
OATP1B2 | |||||
mRNA expression | Fetal development (1%) | 60 days | Increased slowly | Adult age: 60 days (Cui et al., 2012a) and 90d43. Strain: C57BL/6J (Cui et al., 2012a) and CV + GF (Selwyn et al., 2015) (M). Methods: RNA-seq (Cui et al., 2012a) and RT-PCR43 | Cui et al. (2012a); Selwyn et al. (2015) |
OATP2A1 | |||||
mRNA expression | Fetal development (21%–135%) | 23 days | Increased slowly | Adult age: 45 days (Cheng et al., 2005), 60 days (Cui et al., 2012a). Strain: C57BL/6J (Cheng et al., 2005; Cui et al., 2012a) (mixed). Methods: RNA-seq (Cui et al., 2012a) and RT-PCR (Cheng et al., 2005; Cui et al., 2012a) | Cheng et al. (2005); Cui et al. (2012a) |
OATP2B1 | |||||
mRNA expression | Low expression in fetal tissue | 23 days | Increased slowly | Adult age: 45 days (Cheng et al., 2005), 60 days (Cui et al., 2012a), 90 days (Selwyn et al., 2015). Strain: C57BL/6J (Cheng et al., 2005; Cui et al., 2012a) (mixed) and CV + GF (Selwyn et al., 2015) (mixed). Methods: RNA-seq (Cui et al., 2012a) and RT-PCR (Cui et al., 2012a), (Cheng et al., 2005) (Selwyn et al., 2015) | Cheng et al. (2005); Cui et al. (2012a); Selwyn et al. (2015) |
OCT1 | |||||
mRNA expression | M: fetal development (0.05%). F: ND | M: 15–22 days. F: 22–30 days | Increased progressively | Adult age: 45 days (Alnouti et al., 2006), 60 days (Cui et al., 2012a). Strain: C57BL/6J (mixed). Methods: RNA-seq (Cui et al., 2012a) and RT-PCR (Alnouti et al., 2006; Cui et al., 2012a) | Alnouti et al. (2006); Cui et al. (2012a) |
OCTN1 | |||||
mRNA expression | Fetal development (1578%–1975%) | 60 days | Decreased progressively | Adult age: 60 days (Cui et al., 2012a) and 90 days (Selwyn et al., 2015). Strain: C57BL/6J (Cui et al., 2012a) and CV + GF (Selwyn et al., 2015) (M). Methods: RNA-seq (Cui et al., 2012a) and RT-PCR (Selwyn et al., 2015) | Cui et al. (2012a); Selwyn et al. (2015) |
OCTN2 | |||||
mRNA expression | Fetal development (20%–50%) | 1 days | Inconsistent pattern | Adult age: 60 days. Strain: C57BL/6J (M). Methods: RNA-seq | Cui et al. (2012a) |
ASBT, apical sodium-dependent bile acid transporter; bDNA, branched DNA signal amplification assay; F, female; M, male; ND, not detectable; NR, not reported; RNA-seq, RNA-sequencing; RT-PCR, reverse-transcriptase polymerase chain reaction.